- Home
- CELC vs ACLX Comparison
CELC vs ACLX Comparison
Compare CELC & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | ACLX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.7B |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CELC | ACLX |
|---|---|---|
| Price | $88.28 | $115.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 15 |
| Target Price | $112.56 | ★ $118.17 |
| AVG Volume (30 Days) | 1.5M | ★ 12.1M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | N/A | $342.39 |
| Revenue Next Year | $720.19 | $170.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.54 | $60.36 |
| 52 Week High | $151.02 | $115.14 |
Technical Indicators
Market Signals| Indicator | CELC | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 27.54 | 79.86 |
| Support Level | $45.64 | $63.46 |
| Resistance Level | $115.19 | N/A |
| Average True Range (ATR) | 8.54 | 0.11 |
| MACD | -6.01 | -0.62 |
| Stochastic Oscillator | 7.38 | 84.28 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.